Dashboard
Manage Tickers

KALV KalVista Pharmaceuticals, Inc.

Nasdaq kalvista.com


$ 11.95 $ 0.40 (3.47 %)    

Wednesday, 15-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 11.94
$ 11.54
$ 11.00 x 100
$ 12.75 x 25
$ 11.47 - $ 12.06
$ 7.30 - $ 17.28
1,281,565
na
603.25M
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-11-2025 07-31-2025 10-Q
2 07-10-2025 04-30-2025 10-K
3 03-12-2025 01-31-2025 10-Q
4 12-05-2024 10-31-2024 10-Q
5 09-05-2024 07-31-2024 10-Q
6 07-11-2024 04-30-2024 10-K
7 03-11-2024 01-31-2024 10-Q
8 12-07-2023 10-31-2023 10-Q
9 09-07-2023 07-31-2023 10-Q
10 07-07-2023 04-30-2023 10-K
11 03-09-2023 01-31-2023 10-Q
12 12-08-2022 10-31-2022 10-Q
13 09-08-2022 07-31-2022 10-Q
14 07-07-2022 04-30-2022 10-K
15 03-10-2022 01-31-2022 10-Q
16 12-09-2021 10-31-2021 10-Q
17 09-09-2021 07-31-2021 10-Q
18 07-13-2021 04-30-2021 10-K
19 03-11-2021 01-31-2021 10-Q
20 12-10-2020 10-31-2020 10-Q
21 09-14-2020 07-31-2020 10-Q
22 07-01-2020 04-30-2020 10-K
23 03-10-2020 01-31-2020 10-Q
24 12-03-2019 10-31-2019 10-Q
25 09-09-2019 07-31-2019 10-Q
26 07-16-2019 04-30-2019 10-K
27 03-14-2019 01-31-2019 10-Q
28 12-14-2018 10-31-2018 10-Q
29 09-14-2018 07-31-2018 10-Q
30 07-30-2018 04-30-2018 10-K
31 03-16-2018 01-31-2018 10-Q
32 12-14-2017 10-31-2017 10-Q
33 09-14-2017 07-31-2017 10-Q
34 07-27-2017 04-30-2017 10-K
35 03-16-2017 01-31-2017 10-Q
36 11-08-2016 09-30-2016 10-Q
37 08-12-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

kalvista-pharmaceuticals-presents-data-from-konfident-studies-on-ekterly-for-hereditary-angioedema-highlights-need-for-oral-alternatives-to-injectable-therapies
KalVista Pharmaceuticals Presents Data Fro...
10/06/2025 20:03:06

Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient sur...

kalvista-pharma-appoints-bilal-arif-as-coo-effective-october-6-2025
KalVista Pharma Appoints Bilal Arif As COO...
10/06/2025 11:01:36

kalvista-pharmaceuticals-to-present-six-ekterly-sebetralstat-eposters-for-hereditary-angioedema-at-20th-german-allergy-congress-in-dsseldorf-oct-24-2025
KalVista Pharmaceuticals To Present Six EK...
09/26/2025 11:03:40

reported-earlier-kalvista-prices-upsized-125m-offering-of-3250-convertible-senior-notes-due-2031-increased-from-110m-previously-announced
Reported Earlier, KalVista Prices Upsized ...
09/25/2025 06:22:23

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 21:06:04

kalvista-pharmaceuticals-announces-110m-private-offering-of-convertible-senior-notes-due-2031
KalVista Pharmaceuticals Announces $110M P...
09/24/2025 20:05:10

KalVista Pharmaceuticals, Inc. ("KalVista") (NASDAQ:KALV) announced today that it intends to offer, subject to market c...

kalvista-pharma-says-ec-and-swissmedic-approve-ekterly-oral-plasma-kallikrein-inhibitor-for-symptomatic-treatment-of-acute-attacks-of-hae-in-adults
KalVista Pharma Says EC And Swissmedic App...
09/19/2025 11:02:42

First European launch of EKTERLY expected in Germany Q4 2025EKTERLY now approved in the US, EU, UK and Switzerland with additio...

needham-reiterates-buy-on-kalvista-pharmaceuticals-maintains-28-price-target
Needham Reiterates Buy on KalVista Pharmac...
09/12/2025 13:39:04

Needham analyst Serge Belanger reiterates KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy and maintains $28 price target.

jmp-securities-maintains-market-outperform-on-kalvista-pharmaceuticals-raises-price-target-to-28
JMP Securities Maintains Market Outperform...
09/12/2025 11:05:06

JMP Securities analyst Jonathan Wolleben maintains KalVista Pharmaceuticals (NASDAQ:KALV) with a Market Outperform and raise...

kalvista-pharma-q1-eps-112-misses-095-estimate-sales-1426m-miss-2089m-estimate
KalVista Pharma Q1 EPS $(1.12) Misses $(0....
09/11/2025 11:01:00

KalVista Pharma (NASDAQ:KALV) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0...

Core News & Articles
Earnings Scheduled For September 11, 2025
09/11/2025 08:32:11

kalvista-pharmas-earnings-a-preview
KalVista Pharma's Earnings: A Preview
09/10/2025 14:01:25

kalvista-pharmaceuticals-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call
KalVista Pharmaceuticals Earnings Are Immi...
09/10/2025 11:06:11

ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder
Ionis Pharma Wins FDA Nod For First RNA-Ta...
08/21/2025 18:24:53

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch pat...

kalvista-pharmaceuticals-maintains-eu-orphan-designation-for-sebetralstat-securing-potential-10-years-of-market-exclusivity-upon-approval
KalVista Pharmaceuticals Maintains EU Orph...
08/11/2025 11:16:31

Sebetralstat is one of only two hereditary angioedema therapies to maintain orphan designation, underscoring its major contribu...

kalvista-pharmaceuticals-receives-positive-chmp-opinion-sebetralstat-in-sebetralstat
KalVista Pharmaceuticals Receives Positive...
07/25/2025 12:02:48

kalvista-pharmaceuticals-announces-uk-mhra-approval-of-ekterly-for-hereditary-angioedema
KalVista Pharmaceuticals Announces UK MHRA...
07/15/2025 20:07:44

ultragenyx-pharmaceutical-apple-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Ultragenyx Pharmaceutical, Apple And Other...
07/14/2025 12:14:56

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
07/11/2025 10:19:16

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $27 price target.

kalvista-pharmaceuticals-entered-into-sales-agreement-offering-up-to-100m-common-stock
KalVista Pharmaceuticals Entered Into Sale...
07/10/2025 20:34:01

-SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION